PT  - JOURNAL ARTICLE
AU  - Lydeamore, M. J.
AU  - Mitchell, B.G.
AU  - Bucknall, T.
AU  - Cheng, A.C.
AU  - Russo, P.L.
AU  - Stewardson, A. J.
TI  - Burden of five healthcare associated infections in Australia
AID  - 10.1101/2021.10.05.21264587
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.05.21264587
4099  - http://medrxiv.org/content/early/2021/10/08/2021.10.05.21264587.short
4100  - http://medrxiv.org/content/early/2021/10/08/2021.10.05.21264587.full
AB  - Healthcare associated infections (HAIs) are associated with increased morbidity and mortality, but there are few data that quantify the burden of infection nationally in Australia. We used data from an Australian national point prevalence survey to estimate the burden of HAIs amongst adults in Australian public hospitals. The incidence based appropach, introduced by the ECDC Burden of Comunicable Diseases in Europe was used. We estimate that 155,013 HAIs occur in adults admitted to public hospitals in Australia annually, resulting in 6906 deaths. Hospital acquired pneumonia is the most frequent HAI, followed by surgical site infections, and urinary tract infections. We find that blood stream infections contribute a small percentage of HAIs, but contribute the highest number of deaths (3207), more than twice that of the second largest, while pneumonia has the highert impact on years lived with disability. This study is the first time the national burden of HAIs has been estimated for Australia from point prevalence data. The estimated burden is high, and highlights the need for continued investment in HAI prevention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAJS and PLR are supported by an NHMRC Early Career Fellowship (GNT1141398 and APP1156312 respectively). MJL is supported by an NHMRC Project Grant (GNT1156742). BGM is a recipient of a NHMRC Investigator Grant (2021-2026; APP2008392)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For the initial PPS study, ethical approval was granted by the Alfred Health Human Research Ethics Committee (HREC/17/Alfred/203) through the Australian National Mutual Assessment process for all states and territories except for Tasmania, for which a separate approval was obtained from the Tasmanian Health and Medical Human Research Committee (H0016978). This study was based on health information collected and published within the Australian PPS or published within the ECDC PPS and did not require informed consent from participants. Data were provided in aggregated form by age and sex strata, with no personal identifiers.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData requests should be made by email to the corresponding author (M. J. Lydeamore)